Skip to main content
2024 Guide to Patient Support Services

Genentech

2024 PSS Guide

Genentech Oncology Access Solutions

Genentech provides support to help facilitate access to Genentech Oncology medicines for eligible patients. A list of Genentech Oncology medicines, indications, and program information is provided in the Table.

Genentech Oncology Access Solutions

The assistance provided by Genentech Oncology Access Solutions varies based on the patient’s prescribed medication and insurance status.

Genentech Oncology Co-pay Assistance Program

The copay program provides direct financial assistance to commercially insured patients to help with their copays, coinsurance, or other out-of-pocket costs. Patients may pay as little as $5 for their prescribed Genentech Oncology product, with an annual benefit limit of $25,000 per product. Visit Genentech Oncology Co-pay Assistance or call 855-692-6729 to learn more.

Genentech Patient Foundation

Eligible patients who meet specified criteria may qualify to receive their Genentech medication at no cost through the Genentech Patient Foundation.

To help your patient apply, or for more information, visit Genentech Patient Foundation or call 888-941-3331

Independent Foundations

Genentech Access Solutions staff can connect patients to independent copay assistance foundations. Drug-specific listings of foundations are available at Genentech Access..

TABLE Genentech Breast Cancer Drugs

Drugs
Indications
Patient support programs

Drug
Actemra (tocilizumab) injection
Indications
Treatment of cytokine release syndrome induced by CAR T-cell therapy
Patient support programs

Drug
Alecensa (alectinib)
Indications
Treatment of patients with ALK-positive metastatic non–small cell lung cancer as detected by an FDA-approved test
Patient support programs


Drug
Columvi (glofitamab-gxbm) injection
Indications
Treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy
Patient support programs

Drug
Cotellic (cobimetinib)
Indications
Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib; treatment of adults with histiocytic neoplasms as a single agent
Patient support programs

Drug
Erivedge (vismodegib)
Indications
Treatment of adults with metastatic basal-cell carcinoma, or patients with locally advanced basal-cell carcinoma that has recurred following surgery or who are not candidates for surgery and radiation
Patient support programs

Drug
Gavreto (pralsetinib) capsules
Indications
Patient support programs



Drug
Herceptin Hylecta (trastuzumab + hyaluronidase-oysk) injection
Indications
Treatment of HER2-overexpressing breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab
Patient support programs

Drug
Kadcyla (ado-trastuzumab emtansine)
Indications
Treatment of metastatic HER2-positive breast cancer in patients who previously received trastuzumab and a taxane separately or in combination; adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy
Patient support programs

Drug
Lunsumio (mosunetuzu-mab-axgb) injection
Indications
Treatment of adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy
Patient support programs


Drug
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
Indications
Patient support programs

Drug
Polivy (polatuzumab vedotin-piiq) for injection
Indications
In combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or highgrade B-cell lymphoma and who have an International Prognostic Index score of ≥2; in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after ≥2 therapies
Patient support programs


Drug
Rituxan Hycela (rituximab and hyaluronidase human) injection
Indications
Patient support programs



Drug
Venclexta (venetoclax)
Indications
Treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma; treatment, in combination with azacitidine, or decitabine, or low-dose cytarabine, of newly diagnosed acute myeloid leukemia in patients aged ≥75 years, or those who have comorbidities that preclude use of intensive induction chemotherapy
Patient support programs


Drug
Zelboraf (vemurafenib)
Indications
Treatment of unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test; treatment of Erdheim-Chester disease with BRAF V600 mutation
Patient support programs

Avastin (bevacizumab) Indications

First- or second-line treatment of metastatic colorectal cancer (CRC), in combination with 5-fluorouracil–based chemotherapy; second-line treatment of metastatic CRC, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin–based chemotherapy in patients whose disease progressed with a first-line regimen containing bevacizumab; first-line treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell lung cancer, in combination with carboplatin and paclitaxel; recurrent glioblastoma in adults; treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan; treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; treatment of unresectable or metastatic hepatocellular carcinoma, in combination with atezolizumab in patients who have not received prior systemic therapy

Gavreto (pralsetinib) capsules Indications

Treatment of adults with metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test; treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine–refractory (if radioactive iodine is appropriate)

Gazyva (obinutuzumab) Indications

First-line treatment of chronic lymphocytic leukemia, in combination with chlorambucil; in combination with bendamustine followed by obinutuzumab monotherapy, treatment of follicular lymphoma relapsed after, or refractory to, a rituximab-containing regimen; in combination with chemotherapy followed by obinutuzumab monotherapy, for the treatment of patients achieving at least a partial remission, for previously untreated stage II bulky, III, or IV follicular lymphoma

Herceptin (trastuzumab) Indications

Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients based on an FDA-approved companion diagnostic for trastuzumab

Perjeta (pertuzumab) Indications

In combination with trastuzumab and docetaxel, for the treatment of HER2-positive metastatic breast cancer in patients without prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Indications

Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment, in combination with chemotherapy, of patients with HER2-positive early-stage breast cancer at high risk of recurrence; treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease

Rituxan (rituximab) Indications

Treatment of relapsed or refractory, low-grade or follicular CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent; treatment of peviously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; treatment of previously untreated diffuse large B-cell lymphoma (DLBCL), CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens; treatment of pediatric patients aged ≥6 months with previously untreated, advanced-stage, CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapy; treatment of adults with chronic lymphocytic leukemia

Rituxan Hycela (rituximab and hyaluronidase human) injection Indications

Treatment of relapsed or refractory follicular lymphoma (FL); first-line treatment of FL, in combination with chemotherapy, and as maintenance monotherapy in patients with complete or partial response to rituximab plus chemo­therapy; as monotherapy treatment for nonprogressing FL after first-line chemotherapy; treatment of previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone or other anthracycline-based chemotherapy regimens; treatment of chronic lymphocitic leukemia in combination with fludarabine and cyclophosphamide

Rozlytrek (entrectinib) Indications

Treatment of adults with metastatic non–small cell lung cancer with ROS1 mutation, as detected by an FDA-approved test; treatment of adult and pediatric patients ≥1 month of age with solid tumors that have with NTRK gene fusion, as detected by an FDA-approved test, without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy

Tecentriq (atezolizumab) Indications

Monotherapy adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II or IIIA non–small cell lung cancer (NSCLC) and PD-L1 expression, as determined by an FDA-approved test; first-line treatment of adults with metastatic NSCLC and high PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; first-line treatment, in combination with bevacizumab, paclitaxel, and carboplatin, or in combination with paclitaxel protein-bound and carboplatin, of adults with metastatic nonsquamous NSCLC and no EGFR or ALK mutations; treatment of adults with metastatic NSCLC whose disease progressed during or after platinum-containing chemotherapy, or in patients with EGFR or ALK mutations whose disease progressed while using FDA-approved therapy for NSCLC harboring these mutations; first-line treatment, in combination with carboplatin and etoposide, of adults with extensive-stage small-cell lung cancer; treatment, in combination with bevacizumab, of patients with unresectable or metastatic hepatocellular carcinoma who have not received previous systemic therapy; treatment, in combination with cobimetinib and vemurafenib, of patients with unresectable or metastatic melanoma and BRAF V600 mutation; treatment of adult and pediatric patients aged ≥2 years with unresectable or metastatic alveolar soft part sarcoma

Xeloda (capecitabine) Indications

Adjuvant treatment of patients with stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen; perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy; treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen; treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated; treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy; treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen; treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen; adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen